P471 Association of vedolizumab levels with clinical and biochemical markers of inflammation during maintenance therapy in inflammatory bowel disease

Abstract Background The role of TDM in the context of vedolizumab therapy remains unclear. Initial studies have shown a relationship between post induction levels andlong-term outcomes. However, the clinical utility of measuring levels during maintenance treatment remains to be elucidated. Therefore...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2019-01, Vol.13 (Supplement_1), p.S347-S347
Main Authors: Plevris, N, Jones, G R, Jenkinson, P W, Chuah, C S, Lyons, M, Merchant, L M, Pattenden, R J, Arnott, I D, Lees, C W
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background The role of TDM in the context of vedolizumab therapy remains unclear. Initial studies have shown a relationship between post induction levels andlong-term outcomes. However, the clinical utility of measuring levels during maintenance treatment remains to be elucidated. Therefore, we aimed to establish the relationship between trough vedolizumab levels and clinical remission, biochemical remission, and faecal biomarker remission during maintenance therapy. Methods We performed a prospective cross-sectional service evaluation of IBD patients receiving maintenance vedolizumab. All patients had received a minimum of 12 weeks therapy following standard induction (0, 2, 6 ± 10 week dosing). Over a 16 week period, data on clinical activity (HBI or Partial Mayo score), CRP, vedolizumab levels and faecal calprotectin were collected at patients infusions. Clinical remission was defined as HBI
ISSN:1873-9946
1876-4479
DOI:10.1093/ecco-jcc/jjy222.595